BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

864 related articles for article (PubMed ID: 29802206)

  • 1. Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation.
    Yao C; Veleva T; Scott L; Cao S; Li L; Chen G; Jeyabal P; Pan X; Alsina KM; Abu-Taha I; Ghezelbash S; Reynolds CL; Shen YH; LeMaire SA; Schmitz W; Müller FU; El-Armouche A; Tony Eissa N; Beeton C; Nattel S; Wehrens XHT; Dobrev D; Li N
    Circulation; 2018 Nov; 138(20):2227-2242. PubMed ID: 29802206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NLRP3 inflammasome is a key driver of obesity-induced atrial arrhythmias.
    Scott L; Fender AC; Saljic A; Li L; Chen X; Wang X; Linz D; Lang J; Hohl M; Twomey D; Pham TT; Diaz-Lankenau R; Chelu MG; Kamler M; Entman ML; Taffet GE; Sanders P; Dobrev D; Li N
    Cardiovasc Res; 2021 Jun; 117(7):1746-1759. PubMed ID: 33523143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal Hematopoiesis of Indeterminate Potential With Loss of
    Lin AE; Bapat AC; Xiao L; Niroula A; Ye J; Wong WJ; Agrawal M; Farady CJ; Boettcher A; Hergott CB; McConkey M; Flores-Bringas P; Shkolnik V; Bick AG; Milan D; Natarajan P; Libby P; Ellinor PT; Ebert BL
    Circulation; 2024 Apr; 149(18):1419-1434. PubMed ID: 38357791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrial Myocyte NLRP3/CaMKII Nexus Forms a Substrate for Postoperative Atrial Fibrillation.
    Heijman J; Muna AP; Veleva T; Molina CE; Sutanto H; Tekook M; Wang Q; Abu-Taha IH; Gorka M; Künzel S; El-Armouche A; Reichenspurner H; Kamler M; Nikolaev V; Ravens U; Li N; Nattel S; Wehrens XHT; Dobrev D
    Circ Res; 2020 Sep; 127(8):1036-1055. PubMed ID: 32762493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.
    Vande Walle L; Stowe IB; Šácha P; Lee BL; Demon D; Fossoul A; Van Hauwermeiren F; Saavedra PHV; Šimon P; Šubrt V; Kostka L; Stivala CE; Pham VC; Staben ST; Yamazoe S; Konvalinka J; Kayagaki N; Lamkanfi M
    PLoS Biol; 2019 Sep; 17(9):e3000354. PubMed ID: 31525186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice.
    Ren P; Wu D; Appel R; Zhang L; Zhang C; Luo W; Robertson AAB; Cooper MA; Coselli JS; Milewicz DM; Shen YH; LeMaire SA
    J Am Heart Assoc; 2020 Apr; 9(7):e014044. PubMed ID: 32223388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report.
    van der Heijden T; Kritikou E; Venema W; van Duijn J; van Santbrink PJ; Slütter B; Foks AC; Bot I; Kuiper J
    Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1457-1461. PubMed ID: 28596375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of NLRP3-Inflammasome/Caspase-1/Galectin-3 Pathway on Atrial Remodeling in Diabetic Rabbits.
    Wu X; Liu Y; Tu D; Liu X; Niu S; Suo Y; Liu T; Li G; Liu C
    J Cardiovasc Transl Res; 2020 Oct; 13(5):731-740. PubMed ID: 32048199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury.
    Xu X; Yin D; Ren H; Gao W; Li F; Sun D; Wu Y; Zhou S; Lyu L; Yang M; Xiong J; Han L; Jiang R; Zhang J
    Neurobiol Dis; 2018 Sep; 117():15-27. PubMed ID: 29859317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation.
    Primiano MJ; Lefker BA; Bowman MR; Bree AG; Hubeau C; Bonin PD; Mangan M; Dower K; Monks BG; Cushing L; Wang S; Guzova J; Jiao A; Lin LL; Latz E; Hepworth D; Hall JP
    J Immunol; 2016 Sep; 197(6):2421-33. PubMed ID: 27521339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NLRP3 inflammasome inhibition attenuates subacute neurotoxicity induced by acrylamide in vitro and in vivo.
    Sui X; Yang J; Zhang G; Yuan X; Li W; Long J; Luo Y; Li Y; Wang Y
    Toxicology; 2020 Feb; 432():152392. PubMed ID: 32014472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MCC950 blocks enhanced interleukin-1β production in patients with NLRP3 low penetrance variants.
    Schuh E; Groß CJ; Wagner D; Schlüter M; Groß O; Kümpfel T
    Clin Immunol; 2019 Jun; 203():45-52. PubMed ID: 30974290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The NLRP3 inflammasome mediates DSS-induced intestinal inflammation in Nod2 knockout mice.
    Umiker B; Lee HH; Cope J; Ajami NJ; Laine JP; Fregeau C; Ferguson H; Alves SE; Sciammetta N; Kleinschek M; Salmon M
    Innate Immun; 2019 Feb; 25(2):132-143. PubMed ID: 30774010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCC950, a selective NLPR3 inflammasome inhibitor, improves neurologic function and survival after cardiac arrest and resuscitation.
    Jiang M; Li R; Lyu J; Li X; Wang W; Wang Z; Sheng H; Zhang W; Karhausen J; Yang W
    J Neuroinflammation; 2020 Aug; 17(1):256. PubMed ID: 32867797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microglial NLRP3 inflammasome activation mediates IL-1β release and contributes to central sensitization in a recurrent nitroglycerin-induced migraine model.
    He W; Long T; Pan Q; Zhang S; Zhang Y; Zhang D; Qin G; Chen L; Zhou J
    J Neuroinflammation; 2019 Apr; 16(1):78. PubMed ID: 30971286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death.
    Matsuoka T; Yoshimatsu G; Sakata N; Kawakami R; Tanaka T; Yamada T; Yoshida Y; Hasegawa S; Kodama S
    Sci Rep; 2020 Oct; 10(1):17920. PubMed ID: 33087823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.
    Krishnan SM; Ling YH; Huuskes BM; Ferens DM; Saini N; Chan CT; Diep H; Kett MM; Samuel CS; Kemp-Harper BK; Robertson AAB; Cooper MA; Peter K; Latz E; Mansell AS; Sobey CG; Drummond GR; Vinh A
    Cardiovasc Res; 2019 Mar; 115(4):776-787. PubMed ID: 30357309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific Inhibition of the NLRP3 Inflammasome as an Antiinflammatory Strategy in Cystic Fibrosis.
    McElvaney OJ; Zaslona Z; Becker-Flegler K; Palsson-McDermott EM; Boland F; Gunaratnam C; Gulbins E; O'Neill LA; Reeves EP; McElvaney NG
    Am J Respir Crit Care Med; 2019 Dec; 200(11):1381-1391. PubMed ID: 31454256
    [No Abstract]   [Full Text] [Related]  

  • 19. Kv1.5 channel mediates monosodium urate-induced activation of NLRP3 inflammasome in macrophages and arrhythmogenic effects of urate on cardiomyocytes.
    Li P; Kurata Y; Taufiq F; Kuwabara M; Ninomiya H; Higaki K; Tsuneto M; Shirayoshi Y; Lanaspa MA; Hisatome I
    Mol Biol Rep; 2022 Jul; 49(7):5939-5952. PubMed ID: 35368226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geranylgeranyl diphosphate synthase 1 knockdown suppresses NLRP3 inflammasome activity via promoting autophagy in sepsis-induced acute lung injury.
    Li D; Li C; Wang T; Zhang C; Zhu Z; Zhang G; Fang B
    Int Immunopharmacol; 2021 Nov; 100():108106. PubMed ID: 34530204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.